KineMed partnered with Amgen to use KineMed's mass spectrometric Dynamic Proteomics technology to study brain protein homeostasis linked to neurodegenerative diseases

Amgen Inc.

U.S. / Large-Cap Biopharma (>=$50 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

KineMed Inc.

U.S. / Private Biopharma

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced